Onvatilimab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameOnvatilimab
Drug Alias NameCI-8993JNJ-61610588
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionV-domain Ig suppressor of T-cell activation inhibitors
TargetsV-domain Ig suppressor of T-cell activation
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmunext IncJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesCuris Inc
Inactive CompaniesJanssen Research & Development Llc
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A